We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · January 06, 2022

Efficacy of Risankizumab in Patients With Active Psoriatic Arthritis

Annals of the Rheumatic Diseases


Additional Info

Annals of the Rheumatic Diseases
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Ann. Rheum. Dis 2021 Nov 23;[EPub Ahead of Print], A Östör, F Van den Bosch, K Papp, C Asnal, R Blanco, J Aelion, G Alperovich, W Lu, Z Wang, AM Soliman, A Eldred, L Barcomb, A Kivitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading